Nanobiotix (NBTX) Total Current Liabilities (2018 - 2025)

Nanobiotix's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $66.9 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 6.29% year-over-year to $66.9 million in Q4 2025; TTM through Dec 2025 was $66.9 million, a 6.29% increase from a year earlier, with the FY2025 full-year figure at $65.0 million, up 3.17% from the prior year.
• Total Current Liabilities retreated to $66.9 million in Q4 2025 per NBTX's latest filing, from $71.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $71.4 million in Q2 2025 and bottomed at $38.7 million in Q4 2022.
• The 5-year median for Total Current Liabilities is $54.0 million (2023), against an average of $54.2 million.
• Across the five-year window, Total Current Liabilities soared 85.66% in 2021 and dropped 8.17% in 2022, its largest moves.
• Year by year, Total Current Liabilities stood at $42.1 million in 2021, then declined by 8.17% to $38.7 million in 2022, then jumped by 38.64% to $53.7 million in 2023, then rose by 17.36% to $63.0 million in 2024, then increased by 6.29% to $66.9 million in 2025.
• Per Business Quant, the three latest NBTX Total Current Liabilities figures stand at $66.9 million (Q4 2025), $71.4 million (Q2 2025), and $63.0 million (Q4 2024).